Aplastic Anemia

Jodi Mayfield, MD, MS

Institution
University of New Mexico Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Pediatric
About
Dr. Jodi Mayfield is an Assistant Professor of Pediatric Hematology/Oncology and Stem Cell research at the University of New Mexico. She received her MD from the University of New Mexico Health Sciences Center in 2008. She is currently a member of the American Society of Hematology and the Children's Oncology Group. Dr. Mayfield's areas of practice include Stem Cell transplantation, Acute Leukemias, and Bone Marrow failure in Children. Publications Pinto N*, Mayfield JR*, Raca G, et al. Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin

Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.

BACKGROUND:
Fatigue is distressing and affects quality of life (QoL) among patients with myelodysplastic syndrome (MDS), aplastic anemia (AA), and paroxysmal nocturnal hemoglobinuria (PNH).

Consider Allogeneic Bone Marrow Transplantation for Older, Fit Patients with Aplastic Anemia

Effective treatment for severe aplastic anemia (SAA) is either allogeneic bone marrow transplantation (BMT) [1,2] or nontransplant immunosuppressive therapy (IST) containing antithymocyte globulin (ATG) [3,4]. Both treatment approaches have advanced over the recent decades to achieve significantly improved outcomes.

Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia

Our study aimed to compare treatment outcomes between hematopoietic stem cell transplantation (HSCT) from haploidentical donors (HID) and immunosuppressive therapy (IST) in adults with acquired severe aplastic anemia (SAA). The medical records of 113 SAA adults who received IST, including rabbit ATG and cyclosporin (N = 37), or HID HSCT (N = 76) within 6 months of diagnosis at two institutions were retrospectively reviewed. Estimated 8-year overall survival (OS) was comparable between the IST and HID HSCT groups (75.6 vs.
Subscribe to Aplastic Anemia

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.